Polatuzumab Vedotin: First Global Approval

Polatuzumab vedotin (polatuzumab vedotin-piiq; Polivy™) is an antibody–drug conjugate comprising a monoclonal antibody against CD79b (a B cell receptor component) covalently conjugated to the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE) via a cleavable linker. After binding to CD79b on...

Descripción completa

Detalles Bibliográficos
Autor principal: Deeks, Emma D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794237/
https://www.ncbi.nlm.nih.gov/pubmed/31352604
http://dx.doi.org/10.1007/s40265-019-01175-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794237/
https://www.ncbi.nlm.nih.gov/pubmed/31352604
http://dx.doi.org/10.1007/s40265-019-01175-0

Ejemplares similares